Skip to main
IMCR

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Immunocore Holdings is well-positioned for continued success with their ImmTAX platform that has shown positive results in the treatment of a variety of diseases, including mUUM, NSCLC, and autoimmune diseases. Additionally, the company has a strong pipeline of potential treatments in various stages of development, providing opportunities for continued growth. With the anticipated success of their lead product KIMMTRAK and potential future successes in other indications, Immunocore is expected to see significant revenue growth in the coming years. Their strong clinical data and favorable safety profile make them a promising player in the biotech industry.

Bears say

Immunocore Holdings is a commercial-stage biotech company with a deep pipeline in multiple areas, but its main product KIMMTRAK only targets a specific cancer and its other drugs still have a long way to go before approval. Additionally, the regulatory landscape for TCR-based therapeutics is relatively unknown and could impact development and approval timelines. A buy rating and price target of $75 may be premature due to uncertainty and limited market potential in the near-term.

Immunocore Holdings (IMCR) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 6 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $59.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $59.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.